Abstract: Complexes of coronavirus spike proteins, as well as fragments or mutants thereof wherein the fragment or mutant thereof at least contains a receptor binding domain of said coronavirus spike protein, with linoleic acid, or a derivative or a salt or a mimetic thereof. Methods for producing the complexes of the invention by incubating coronavirus spike proteins with linoleic acid or a derivative or a salt or a mimetic thereof. . In vitro methods for identifying molecules which have therapeutic potential for diseases caused by coronaviruses by contacting the molecule with a coronavirus spike protein and linoleic acid or a derivative or salt or mimetic thereof. A method of treatment of coronavirus infection by administration of linoleic acid, or a derivative, a salt or a mimetic thereof to a subject in need thereof, by administration of an aerosol formulation or dry powder formulation to the respiratory tract, preferably by nasal administration.

Abstract: The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope. Additional cargo, e.g. drugs, proteins, or nucleic acids, can reversibly or irreversibly attached to the VLP via engineered fibre protein fragments.

Abstract: An engineered adenovirus penton base protomer, wherein the penton base protomer comprises a first RGD-loop, a second RGD-loop, a variable loop (V loop), an Adenovirus fiber protein binding cleft, and an N-terminal domain; wherein at least one of the first RGD-loop, the second RGD-loop, and the V loop comprises at least one inserted non-adenoviral antigenic polypeptide; and wherein the engineered adenovirus penton base protomer is capable of assembling into virus-like particles (VLPs).

Abstract: The present invention deals with heterotrimeric AMP-activated protein kinase (AMPK) comprising a fluorophore pair wherein the conformational change can be measured by FRET. It represents an advanced tool to screen and identify AMPK interactors in vitro and in cells in vivo. Such invention can also be considered as a reporter of the cellular energy status as it allows the spatiotemporal monitoring, in situ, of fluctuations in the ratio of AMP and ADP versus ATP.

Abstract: The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope. Additional cargo, e.g. drugs, proteins, or nucleic acids, can reversibly or irreversibly attached to the VLP via engineered fibre protein fragments.

Abstract: The invention relates to a method of preparing engineered target polypeptides (TP) comprising in its amino acid sequence one or more, identical or different, non-canonical amino acid (ncAA) residues, by expressing said TP in an insect cell line (ICL) and by expressing novel orthogonal bacterial aminoacyl tRNA synthetase/tRNA pairs in said ICL; a baculoviral shuttle vector (bacmid) suitable or introducing the genetic information of said orthogonal tRNA synthetase/tRNA into said ILC; particular expression cassettes for expressing said particular tRNAs in said ILC; TPs obtained by said method; as we as a kit for preparing said TPs.

Abstract: The present invention deals with heterotrimeric AMP-activated protein kinase (AMPK) comprising a fluorophore pair wherein the conformational change can be measured by FRET. It represents an advanced tool to screen and identify AMPK interactors in vitro and in cells in vivo. Such invention can also be considered as a reporter of the cellular energy status as it allows the spatiotemporal monitoring, in situ, of fluctuations in the ratio of AMP and ADP versus ATP.

Abstract: The present invention relates to a recombinant polynucleotide encoding a polygene coding for at least three polypeptides wherein at least one of the genes constituting the polygene is of non-viral origin, at least two of the polypeptides encoded by the genes constituting the polygene are each capable of at least transiently interacting with at least one other polypeptide encoded by a gene of said polygene, and the genes constituting the polygene are each connected to one another by a sequence coding for at least one protease cleavage site. The present invention also relates to polyproteins encoded by the polygene. Further embodiments of the present invention are a vector containing the recombinant polypeptide, a host cell containing the recombinant polypeptide and/or the vector and a non-human transgenic animal transformed with the recombinant polypeptide and/or the vector. The present invention also relates to methods for the production of the polynucleotide and for the manufacture of multiprotein complexes.

Abstract: The present invention relates to a recombinant polynucleotide encoding a polygene coding for at least three polypeptides wherein at least one of the genes constituting the polygene is of non-viral origin, at least two of the polypeptides encoded by the genes constituting the polygene are each capable of at least transiently interacting with at least one other polypeptide encoded by a gene of said polygene, and the genes constituting the polygene are each connected to one mother by a sequence coding for at least one protease cleavage site. The present invention also relates to polyproteins encoded by the polygene. Further embodiments of the present invention are a vector containing the recombinant polypeptide, a host cell containing the recombinant polypeptide and/or the vector and a non-human transgenic animal transformed with the recombinant polypeptide and/or the vector. The present invention also relates to methods for the production of the polynucleotide and for the manufacture of multiprotein complexes.

Abstract: Polynucleotides for multigene applications comprising a novel functional arrangement, as well as vectors, host cells, and recombinant animals comprising the polynucleotides are described. Methods for generating multigene expression cassettes, methods for producing multiprotein complexes in vitro and in vivo, and methods for producing a vaccine are also disclosed. Further encompassed are methods for screening protein complex interactions or modifications of proteins, and methods for in vitro or in vivo screening of candidate compounds capable of protein complex interactions, modifications of proteins, inhibiting protein complex interactions or inhibiting modifications of proteins. Methods of use of the polynucleotides, vectors, host cells or recombinant animals for (i) preparing a medicament for gene therapy, for (ii) the recombinant production of multiprotein complexes, (iii) for producing a vaccine, or (iv) for screening compounds of interest.

Abstract: The present invention is based on the discovery that large parts of the genome of nucleopolyhedtovirus (NPV)-alpha baculovirus clade Ia viruses can be deleted with out deleterious effect on the usability of the virus comprising such genome in the infection of cells in cell culture. Accordingly, the present invention provides NPY-alpha baculovirus clade Ia genome which is reduced in size in comparison to the respective native NPV-alpha baculovirus clade Ia genome, such genomes comprising heterologous nucleotides, viruses comprising either of these genomes, cells infected with such viruses and methods for producing such viruses and cells.

Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.

Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector, a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.

Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector, a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.

Abstract: The present invention relates to a recombinant polynucleotide encoding a polygene coding for at least three polypeptides wherein at least one of the genes constituting the polygene is of non-viral origin, at least two of the polypeptides encoded by the genes constituting the polygene are each capable of at least transiently interacting with at least one other polypeptide encoded by a gene of said polygene, and the genes constituting the polygene are each connected to one mother by a sequence coding for at least one protease cleavage site. The present invention also relates to polyproteins encoded by the polygene. Further embodiments of the present invention are a vector containing the recombinant polypeptide, a host cell containing the recombinant polypeptide and/or the vector and a non-human transgenic animal transformed with the recombinant polypeptide and/or the vector. The present invention also relates to methods for the production of the polynucleotide and for the manufacture of multiprotein complexes.

Abstract: The present invention relates to polynucleotides for multigene applications comprising a novel functional arrangement, as well as vectors, host cells, and recombinant animals comprising said polynucleotides. In addition, the present invention is directed to methods for generating multigene expression cassettes, methods for producing multiprotein complexes in vitro and in vivo, and methods for producing a vaccine. Furthermore, the present invention encompasses methods for screening protein complex interactions or modifications of proteins, and methods for the in vitro or in vivo screening of candidate compounds capable of protein complex interactions or modifications of proteins or capable of inhibiting protein complex interactions or inhibiting modifications of proteins.